참고문헌
- http://www.goldcopd.org.
- Hanania, N. A. and Donohue, J. F. (2007) Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc. Am. Thorac. Soc. 4, 526-534. https://doi.org/10.1513/pats.200701-016FM
- Tjia, J. F., Colbert, J. and Back, D. J. (1996) Theophylline metabolism in human liver microsomes: inhibition studies. J. Pharmacol. Exp. Ther. 276, 912-917.
- Derkenne, S., Curran, C. P., Shertzer, H. G., Dalton, T. P., Dragin, N. and Nebert, D. W. (2005) Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. Pharmacogenet. Genomics. 15, 503-511. https://doi.org/10.1097/01.fpc.0000167326.00411.50
- Potkin, S. G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K. and Gerber, B. (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J. Clin. Psychiatry. 55 (Suppl B), 133-136.
- Barnes, P. J. (2005) Theophylline in chronic obstructive pulmonary disease: new horizons. Proc. Am. Thorac. Soc. 334-339.
- http://www.cypalleles.ki.se/cyp1a2.htm.
- Nakajima, M., Yokoi, T., Mizutani, M., Kinoshita, M., Funayama, M. and Kamataki, T. (1999) Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 125, 803-808. https://doi.org/10.1093/oxfordjournals.jbchem.a022352
- Sachse, C., Brockmoller, J., Bauer, S. and Roots, I. (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445-449. https://doi.org/10.1046/j.1365-2125.1999.00898.x
- Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L. and Ingelman-Sundberg, M. (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. 64, 659-669. https://doi.org/10.1124/mol.64.3.659
- Allorge, D., Chevalier, D., Lo-Guidice, J. M., Cauffiez, C., Suard, F., Baumann, P., Eap, C. B. and Broly, F. (2003) Identification of a novel splice-site mutation in the CYP1A2 gene. Br. J. Clin. Pharmacol. 56, 341-344. https://doi.org/10.1046/j.1365-2125.2003.01858.x
- Murayama, N., Soyama, A., Saito, Y., Nakajima, Y., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kimura, H., Goto, Y., Saitoh, O., Katoh, M., Ohnuma, T., Kawai, M., Sugai, K., Ohtsuki, T., Suzuki, C., Minami, N., Ozawa, S. and Sawada, J. (2004) Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J. Pharmacol. Exp. Ther. 308, 300-306. https://doi.org/10.1124/jpet.103.055798
- Arif, E., Vibhuti, A., Alam, P., Deepak, D., Singh, B., Athar, M. and Pasha, M. A. (2007) Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin. Chim. Acta. 382, 37-42. https://doi.org/10.1016/j.cca.2007.03.013
- Korytina, G. F., Akhmadishina, L. Z., Kochetova, O. V., Zagidullin, Sh. Z. and Viktorova, T. V. (2008) Association of cytochrome P450 genes polymorphisms (CYP1A1 and CYP1A2) with the development of chronic obstructive pulmonary disease in Bashkortostan. Mol. Biol. (Mosk) 42, 32-41.
- Jiang, Z., Dragin, N., Jorge-Nebert, L. F., Martin, M. V., Guengerich, F. P., Aklillu, E., Ingelman-Sundberg, M., Hammons, G. J., Lyn-Cook, B. D., Kadlubar, F. F., Saldana, S. N., Sorter, M., Vinks, A. A., Nassr, N., von Richter, O., Jin, L. and Nebert, D. W. (2006) Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet. Genomics. 16, 359-367. https://doi.org/10.1097/01.fpc.0000204994.99429.46
- Ghotbi, R., Christensen, M., Roh, H. K., Ingelman-Sundberg, M., Aklillu, E. and Bertilsson, L. (2007) Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol. 63, 537-546. https://doi.org/10.1007/s00228-007-0288-2
- Takata, K., Saruwatari, J., Nakada, N., Nakagawa, M., Fukuda, K., Tanaka, F., Takenaka, S., Mihara, S., Marubayashi, T. and Nakagawa, K. (2006) Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur. J. Clin. Pharmacol. 62, 23-28. https://doi.org/10.1007/s00228-005-0057-z
- Obase, Y., Shimoda, T., Kawano, T., Saeki, S., Tomari, S. Y., Mitsuta-Izaki, K., Matsuse, H., Kinoshita, M. and Kohno, S. (2003) Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin. Pharmacol. Ther. 73, 468-474. https://doi.org/10.1016/S0009-9236(03)00013-4
- Skarke, C., Kirchhof, A., Geisslinger, G. and Lotsch, J. (2005) Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. Eur. J. Clin Pharmacol. 61, 887-892. https://doi.org/10.1007/s00228-005-0029-3
- Soyama, A., Saito, Y., Hanioka, N., Maekawa, K., Komamura, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ueno, K., Goto, Y., Kimura, H., Katoh, M., Sugai, K., Saitoh, O., Kawai, M., Ohnuma, T., Ohtsuki, T., Suzuki, C., Minami, N., Kamatani, N., Ozawa, S. and Sawada, J. (2005) Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug. Metab. Pharmacokinet. 20, 24-33. https://doi.org/10.2133/dmpk.20.24
- Bernauer, U., Heinrich-Hirsch, B., Tonnies, M., Peter-Matthias, W. and Gundert-Remy, U. (2006) Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol. Lett. 164, 278-288. https://doi.org/10.1016/j.toxlet.2006.01.007
- Fukami, T., Nakajima, M., Sakai, H., Katoh, M. and Yokoi, T. (2007) CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab. Dispos. 35, 335-339.
- Zhang, Z. Y. and Kaminsky, L. S. (1995) Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem. Pharmacol. 50, 205-211. https://doi.org/10.1016/0006-2952(95)00120-O
- Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J. and Kamataki, T. (1999) Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn. J. Cancer. Res. 90, 899-902. https://doi.org/10.1111/j.1349-7006.1999.tb00832.x
피인용 문헌
- Pharmacogenetics of chronic obstructive pulmonary disease vol.14, pp.10, 2013, https://doi.org/10.2217/pgs.13.107
- Does “smoker’s paradox” exist in clopidogrel-treated Turkish patients with acute coronary syndrome vol.27, pp.3, 2016, https://doi.org/10.3109/09537104.2015.1083544
- Association between CommonCYP1A2Polymorphisms and Theophylline Metabolism in Non-smoking Healthy Volunteers vol.112, pp.4, 2013, https://doi.org/10.1111/bcpt.12038
- Population Pharmacokinetics of Theophylline in Premature Korean Infants vol.35, pp.3, 2013, https://doi.org/10.1097/FTD.0b013e3182866695
- Genetic polymorphism analysis of the drug-metabolizing enzyme CYP1A2 in a Uyghur Chinese population: a pilot study vol.46, pp.6, 2016, https://doi.org/10.3109/00498254.2015.1089367
- Theophylline: a review of population pharmacokinetic analyses vol.41, pp.6, 2016, https://doi.org/10.1111/jcpt.12435
- Genetic polymorphisms in promoter and intronic regions of CYP1A2 gene in Roma and Hungarian population samples vol.38, pp.3, 2014, https://doi.org/10.1016/j.etap.2014.09.012
- Genetic polymorphisms in metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine vol.33, pp.1, 2013, https://doi.org/10.1002/jat.1712
- Functional characterization of 20 allelic variants of CYP1A2 vol.30, pp.3, 2015, https://doi.org/10.1016/j.dmpk.2015.03.001
- Population pharmacokinetics of theophylline in adult Chinese patients with asthma and chronic obstructive pulmonary disease pp.2210-7711, 2018, https://doi.org/10.1007/s11096-018-0636-6